Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team
Press release

BioStock: Spago Nanomedical's CDO on study submission

Spago Nanomedical

Spago Nanomedical recently submitted the application to start the phase I/IIa study with Tumorad in Australia. Spago's Chief Development Officer Paul Hargreaves visited BioStock's studio to talk about the new radionuclide therapy and the upcoming study.

Watch the interview with Spago Nanomedical's CDO Paul Hargreaves at biostock.se:

https://www.biostock.se/en/2023/05/spago-nanomedicals-cdo-on-study-submission/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.